Part:BBa_K3132020
SynNotch-anti-HER2
In our SynNotch system, we retained the functional sequence of the transmembrane domain from α-CD19 Notch. At the N-terminus, we used anti-HER2 scFV(BBa_K3132005) as the extracellular domain of our synNotch recepter to specifically recognize HER2, the tumor surface antigen we chose as the target, so that our engineered NK cells obtain the ability to response to HER2 on the surface of the cancer cell. We put Gal4-VP64 (a fusion protein) in the downstream of the transmembrane domain, as the intracelluar domain of the synNotch. In the presence of tumor marker antigen HER2, SynNotch protein will be cleaved, and thus Gal4-VP64 fusion protein will be detached from the cell membrane. The released Gal4-VP64 will be located into nuclei and recognize UAS sequence in its corresponding promoter UAS_MinimalCMV (BBa_K3132004) and then these two proteins combine together, which enable our CAR and IL-2 gene expressed with high efficiency, performing killing activity and inducing signal molecules secretion. The relevant experiments have confirmed our our expectations.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12INCOMPATIBLE WITH RFC[12]Illegal NotI site found at 1642
- 21INCOMPATIBLE WITH RFC[21]Illegal BglII site found at 56
- 23COMPATIBLE WITH RFC[23]
- 25INCOMPATIBLE WITH RFC[25]Illegal NgoMIV site found at 985
Illegal NgoMIV site found at 1162
Illegal NgoMIV site found at 1700
Illegal NgoMIV site found at 1748
Illegal NgoMIV site found at 1883 - 1000INCOMPATIBLE WITH RFC[1000]Illegal SapI.rc site found at 1321
| None |